Read More Pharma Industry News Is TPST-2003’s early efficacy enough to disrupt the current CAR-T landscape in multiple myeloma Can TPST-2003 disrupt CAR-T therapy in multiple myeloma? Explore what Tempest Therapeutics, Inc.’s strategy means for investors and the industry. bySoujanya RaviApril 24, 2026